IP Library Granted Patent US 9,399,799
Granted Patent B2
US 9,399,799 · App. 14/518,114 · Granted Jul 26, 2016

Methods and compositions for incorporating nucleotides

Inventors: Steven Gordon (Weston, MA); Jerzy Olejnik (Brookline, MA)
Assignee: INTELLIGENT BIOSYSTEMS, INC.
C12Q1/6869G01N21/6428G01N21/05G01N2021/0346G01N2021/058G01N2021/6419G01N2021/6421G01N2021/6441G01N2021/6471
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,799
App. No.
14/518,114
Granted
Jul 26, 2016
Kind
B2
Abstract

The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Claims (19)

1. A composition comprising i) a first plurality of labeled reversible terminators comprising nucleotide analogues wherein each nucleotide analogue is labeled with a unique label and contains a removable chemical moiety capping the 3′-OH group; and ii) a second plurality of unlabeled reversible terminators comprising nucleotide analogues wherein each nucleotide analogue is unlabeled and contains a removable chemical moiety capping the 3′-OH group, wherein the second plurality of nucleotide analogues is present in said solution at a higher concentration than said first plurality of nucleotide analogues.

2. The composition of claim 1 , wherein said nucleotide analogues are in solution.

3. The composition of claim 1 , wherein said second plurality of nucleotide analogues is present at a concentration between 1 μM and 100 μM.

4. The composition of claim 1 , wherein said first plurality of nucleotide analogues is present at a concentration between 1 μM and 1 μM.

5. The composition of claim 1 , wherein said first plurality of nucleotide analogues comprises four different nucleotide analogues.

6. The composition of claim 5 , wherein said second plurality of nucleotide analogues comprises four different nucleotide analogues.

7. The composition of claim 5 , wherein each of said four different nucleotide analogues comprises a unique label, said label selected from the group consisting of BODIPY, Rhodamine, Carboxyrhodamine, and Cyanine.

8. The composition of claim 1 , wherein said removable chemical moiety comprises a disulfide bond.

9. The composition of claim 1 , wherein said removable chemical moiety comprises an azido group.

10. The composition of claim 1 , wherein said removable chemical moiety comprises an azidomethyl ether.

11. The composition of claim 1 , wherein said label is attached via a cleavable linker.

12. The composition of claim 10 , wherein said cleavable linker comprises a disulfide bond.

13. The composition of claim 10 , wherein said removable chemical moiety comprises an azido group and said cleavable linker comprises a disulfide bond.

14. The composition of claim 1 , further comprising polymerase.

15. A composition comprising i) a first plurality of labeled reversible terminators comprising nucleotide analogues comprising four different nucleotide analogues, wherein each different nucleotide analogue is labeled with a unique label and contains a removable chemical moiety capping the 3′-OH group; and ii) a second plurality of unlabeled reversible terminators comprising nucleotide analogues comprising four different nucleotide analogues, wherein each nucleotide analogue is unlabeled and contains a removable chemical moiety capping the 3′-OH group, wherein the second plurality of nucleotide analogues is present in said solution at a higher concentration than said first plurality of nucleotide analogues.

16. The composition of claim 15 , wherein said nucleotide analogues are in solution.

17. The composition of claim 15 , wherein said second plurality of nucleotide analogues is present at a concentration between 1 μM and 100 μM.

18. The composition of claim 15 , wherein said first plurality of nucleotide analogues is present at a concentration between 1 nM and 1 μM.

19. The composition of claim 15 , further comprising a polymerase.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 24, 2023
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: ISOPLEXIS CORPORATION
Reel/Frame 063235/0942 →
PATENT PURCHASE AGREEMENT Recorded Jul 30, 2021
From: QIAGEN SCIENCES, LLC
To: ISOPLEXIS CORPORATION
Reel/Frame 057043/0629 →
SECURITY AGREEMENT Recorded May 28, 2021
From: ISOPLEXIS CORPORATION
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 056421/0929 →
MERGER Recorded Nov 8, 2018
From: QIAGEN WALTHAM, INC.
To: QIAGEN SCIENCES, LLC
Reel/Frame 047923/0815 →
CHANGE OF NAME Recorded May 17, 2018
From: INTELLIGENT BIO-SYSTEMS, INC.
To: QIAGEN WALTHAM, INC.
Reel/Frame 047132/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2014
From: GORDON, STEVEN; OLEJNIK, JERZY
To: INTELLIGENT BIO-SYSTEMS, INC.
Reel/Frame 034545/0093 →
Continuity (4)
Division 13305415 · Nov 28, 2011
Continuation 12405779 · Mar 17, 2009
Provisional Application 61037845 · Mar 19, 2008
Related Publication 20150191783A1 · Jul 9, 2015